胞质多聚腺苷酸结合蛋白4在肝癌中的表达及其功能

doi:10.3969/j.issn.1004-616x.2025.03.006

Abstract

Abstract: OBJECTIVE： To investigate the expression characteristics， prognostic significance and functional role of cytoplasmic polyadenylate-binding protein 4 (PABPC4) in liver cancers. METHODS： RNA sequencing data of liver cancers from The Cancer Genome Atlas (TCGA) were downloaded to analyze relationships between PABPC4 expression and patient prognosis. PABPC4 knockdown and overexpression liver cancer cell lines were constructed， and expression of PABPC4， its stemness-related indexes mRNA and protein in cells were detected by real-time quantitative PCR and Western blot. Effects of PABPC4 on cell proliferation，migration，invasion and stemness were studied by CCK-8 method，plate colony formation assay， cell scratch assay and Transwell assay. RESULTS： Expression levels of PABPC4 in liver cancer tissues gradually increased with increase of pathological grade. Patients with high expression had shorter overall survival and recurrence-free survival time (P<0.05). In tumor tissues with the high expression showed upregulated PABPC4，Wnt signaling pathway-related proteins. The successfully constructed HLF cells showed stable knockdown of PABPC4 and Huh7 cells with stable overexpression. Functional experiments showed that knockdown of PABPC4 showed significantly inhibited cell proliferation， migration， invasion and colony formation (P<0.05). Overexpression of PABPC4 had the opposite effect (P<0.05). In addition， after high expression of PABPC4， the mRNA expression levels of cell stemness-related indicators (Nanog， OCT4， CD133， SOX2) were significantly increased. CONCLUSION： PABPC4 was highly expressed and was correlated with poor prognosis in liver cancer patients. PABPC4 enhanced cancer cell stemness and promoted proliferation， survival， migration， and invasion of cancer cells. Therefore， PABPC4 is a potential target for prognostic prediction and therapeutic intervention in liver cancer.

Key words: liver cancer, PABPC4, prognostic prediction, proliferation and survival, migration and invasion, cell stemness

CLC Number:

R735.7

LIU Xinmiao, GAO Hongjun, KANG Yan, ZHANG Yun, SUN Yulin. Expression and function of PABPC4 in liver cancers[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(3): 209-214,220.

References

[1] WU Z H, XIA F N, LIN R. Global burden of cancer and associated risk factors in 204 countries and territories, 1980-2021: a systematic analysis for the GBD 2021[J]. J Hematol Oncol, 2024, 17(1): 119.
[2] FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314.
[3] 国家卫生健康委员会医政司.原发性肝癌诊疗指南(2024年版) [EB/OL].[2025-03-27].http: //www.nhc.gov.cn/cms-search/ downFiles/48cd549a54204ab1a6247e86adb2dea2.pdf.
[4] LLOVET J M, PINYOL R, KELLEY R K, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma[J]. Nat Cancer, 2022, 3(4): 386-401.
[5] MANGUS D A, EVANS M C, JACOBSON A. Poly(A)-binding proteins: multifunctional scaffolds for the post-transcriptional control of gene expression[J]. Genome Biol, 2003, 4(7): 223.
[6] BURGESS H M, GRAY N K. mRNA-specific regulation of translation by poly(A)-binding proteins[J]. Biochem Soc Trans, 2010, 38(6): 1517-1522.
[7] CRAIG A W, HAGHIGHAT A, YU A T, et al. Interaction of polyadenylate-binding protein with the eIF4G homologue PAIP enhances translation[J]. Nature, 1998, 392(6675): 520-523.
[8] KINI H K, KONG J, LIEBHABER S A. Cytoplasmic poly(A) binding protein C4 serves a critical role in erythroid differentiation[J]. Mol Cell Biol, 2014, 34(7): 1300-1309.
[9] GU Y Z, WEI X Y, SUN Y L, et al. miR-192-5p silencing by genetic aberrations is a key event in hepatocellular carcinomas with cancer stem cell features[J]. Cancer Res, 2019, 79(5): 941- 953.
[10] SMITH R W P, BLEE T K P, GRAY N K. Poly(A)-binding proteins are required for diverse biological processes in metazoans[J]. Biochem Soc Trans, 2014, 42(4): 1229-1237.
[11] BROOK M, GRAY N K. The role of mammalian poly (A)-binding proteins in co-ordinating mRNA turnover[J]. Biochem Soc Trans, 2012, 40(4): 856-864.
[12] FATSCHER T, BOEHM V, WEICHE B, et al. The interaction of cytoplasmic poly(A)-binding protein with eukaryotic initiation factor 4G suppresses nonsense-mediated mRNA decay[J]. RNA, 2014, 20(10): 1579-1592.
[13] LI C Y, HAN T T, LI Q R, et al. MKRN3-mediated ubiquitination of Poly(A)-binding proteins modulates the stability and translation of GNRH1 mRNA in mammalian puberty[J]. Nucleic Acids Res, 2021, 49(7): 3796-3813.
[14] OLIVEIRA A G, OLIVEIRA L D, CRUZ M V, et al. Interaction between poly(A)-binding protein PABPC4 and nuclear receptor corepressor NCoR1 modulates a metabolic stress response[J]. J Biol Chem, 2023, 299(6): 104702.
[15] JIAO Y J, KONG N, WANG H, et al. PABPC4 broadly inhibits coronavirus replication by degrading nucleocapsid protein through selective autophagy[J]. Microbiol Spectr, 2021, 9(2): e0090821.
[16] GUO W H, LI J Y, HUANG H B, et al. LncRNA PCIR is an oncogenic driver via strengthen the binding of TAB3 and PABPC4 in triple negative breast cancer[J]. Front Oncol, 2021, 11: 630300.
[17] LIU D, YIN B, WANG Q, et al. Cytoplasmic poly(A) binding protein 4 is highly expressed in human colorectal cancer and correlates with better prognosis[J]. J Genet Genomics, 2012, 39(8): 369-374.
[18] WANG X Y, LIN Y, LI Z, et al. Alternative polyadenylation regulatory factors signature for survival prediction in kidney renal cell carcinoma[J]. Cancer Inform, 2024, 23: 11769351231180789.
[19] SONG H, GE Y, XU J, et al. Identification and validation of novel signature associated with hepatocellular carcinoma prognosis using Single-cell and WGCNA analysis[J]. Int J Med Sci, 2023, 20(7): 870-887.
[20] MENG K, LU S H, LI Y Y, et al. LINC00493-encoded microprotein SMIM26 exerts anti-metastatic activity in renal cell carcinoma[J]. EMBO Rep, 2023, 24(6): e56282.
[21] JIANG X, WANG G G, LIU Y Y, et al. A novel long non-coding RNA RP11-286H15.1 represses hepatocellular carcinoma progression by promoting ubiquitination of PABPC4[J]. Cancer Lett, 2021, 499: 109-121.

Expression and function of PABPC4 in liver cancers

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 5

Recommended Articles

Metrics

Comments

[1]	WU Xiuqian, LIANG Tairong, ZHUANG Xuelong, WANG Xingxing, HUANG Haihua. Involvement of DKK-1 and NNMT in clinicopathology and prognosis among liver cancer patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(6): 452-456,462.
[2]	WANG Yinong, LIU Guozheng, XIE Guanchao, FENG Dan, LI Sai, CAI Yan, ZHANG Yu, WANG Mingrong, HAO Jiajie. Inhibitory effects of ANXA2 knockdown on malignant phenotype of esophageal squamous carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 445-451.
[3]	JIAO Wenpeng, HOU Lin, CUI Meijuan, JIAO Wenjing, MA Ming, ZHANG Jinyan. Expression of miR-93-5p and miR-106b-5p in alcohol-related liver cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 430-434.
[4]	HU Qiong, YOU Shuping, LIU Tao, WANG Bo, LIU Xin, JIANG Yuandong. An investigation on the anti-liver cancer effect of cistanche [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(3): 194-199.
[5]	HUANG Yongsheng, LIU Wenbin, HAN Fei, CUI Zhihong, AO Lin, CAO Jia, LIU Jinyi. MPDZ copy number variations, expression and prognostic value in liver cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(3): 161-165.